---
figid: PMC4116492__oncotarget-05-3426-g001
figlink: /pmc/articles/PMC4116492/figure/F1/
number: F1
caption: In response to DNA damage or replicaiton stress, ATM/CHK2 and ATR/CHK1 checkpoints
  are activated, thereby promoting DNA damage repair via multiple mechanisms including
  NER, HR and TLS. DNA damage repair intermediates activate ATM/CHK2 and ATR/CHK1
  checkpoints. FANCD2-mediated signaling pathway is one of the key coordinators between
  ATM/ATR checkpoints and the repair system of NER, HR and TLS. Downregulation of
  FANCD2 by targeting RTK-PI3K-AKT-mTOR would sensitize cancer cells to DNA damage
  agents. Directly targeting FANCD2 (marked with X) could be a promising strategy
  for cancer therapy. AZD8055 (AstraZeneca), mTOR kinase inhibitor; MK2206 (Merck),
  AKT kinase inhibitor; PD0332991 (Pfizer), CDK4/6 kinase inhibitor; PF4708671 (Pfizer),
  S6K1 kinase inhibitor. NER, nucleotide excision repair; HR, homologous recombination;
  TLS, translesion DNA synthesis; RTK, receptor tyrosine kinase; IRS, insulin receptor
  substrate.
pmcid: PMC4116492
papertitle: Targeting FANCD2 for therapy sensitization.
reftext: Changxian Shen, et al. Oncotarget. 2014 Jun;5(11):3426-3427.
pmc_ranked_result_index: '1053'
pathway_score: 0.9603359
filename: oncotarget-05-3426-g001.jpg
figtitle: Targeting FANCD2 for therapy sensitization
year: '2014'
organisms: Homo sapiens
ndex: 60154f67-dea9-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4116492__oncotarget-05-3426-g001.html
  '@type': Dataset
  description: In response to DNA damage or replicaiton stress, ATM/CHK2 and ATR/CHK1
    checkpoints are activated, thereby promoting DNA damage repair via multiple mechanisms
    including NER, HR and TLS. DNA damage repair intermediates activate ATM/CHK2 and
    ATR/CHK1 checkpoints. FANCD2-mediated signaling pathway is one of the key coordinators
    between ATM/ATR checkpoints and the repair system of NER, HR and TLS. Downregulation
    of FANCD2 by targeting RTK-PI3K-AKT-mTOR would sensitize cancer cells to DNA damage
    agents. Directly targeting FANCD2 (marked with X) could be a promising strategy
    for cancer therapy. AZD8055 (AstraZeneca), mTOR kinase inhibitor; MK2206 (Merck),
    AKT kinase inhibitor; PD0332991 (Pfizer), CDK4/6 kinase inhibitor; PF4708671 (Pfizer),
    S6K1 kinase inhibitor. NER, nucleotide excision repair; HR, homologous recombination;
    TLS, translesion DNA synthesis; RTK, receptor tyrosine kinase; IRS, insulin receptor
    substrate.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IRS1
  - IRS2
  - CHEK1
  - CHEK2
  - FANCD2
  - ATR
  - CDK4
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - IRS4
  - PIK3R5
  - PIK3CB
  - NR1H2
  - ATM
  - AKT2
  - AKT3
  - PIK3R4
  - PIK3R6
  - FUS
  - RPS6KB1
  - PIK3CA
  - AKT1
  - LY294002 H
  - AZD8055
  - PF4708671
  - Cancer
genes:
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: CHK1
  symbol: CHK1
  source: hgnc_alias_symbol
  hgnc_symbol: CHEK1
  entrez: '1111'
- word: CHK2
  symbol: CHK2
  source: hgnc_alias_symbol
  hgnc_symbol: CHEK2
  entrez: '11200'
- word: FANCD2
  symbol: FANCD2
  source: hgnc_symbol
  hgnc_symbol: FANCD2
  entrez: '2177'
- word: ATR
  symbol: ATR
  source: hgnc_symbol
  hgnc_symbol: ATR
  entrez: '545'
- word: CDK4
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS4
  entrez: '8471'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: NER
  symbol: NER
  source: hgnc_alias_symbol
  hgnc_symbol: NR1H2
  entrez: '7376'
- word: ATM
  symbol: ATM
  source: hgnc_symbol
  hgnc_symbol: ATM
  entrez: '472'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: TLS
  symbol: TLS
  source: hgnc_alias_symbol
  hgnc_symbol: FUS
  entrez: '2521'
- word: S6K1
  symbol: S6K1
  source: hgnc_alias_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: (PI3K)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
chemicals:
- word: LY294002 H
  source: MESH
  identifier: C085911
- word: AZD8055
  source: MESH
  identifier: C546624
- word: PF4708671
  source: MESH
  identifier: C552719
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC4116492__F1
redirect_from: /figures/PMC4116492__F1
figtype: Figure
---
